83 / 144
83
8. Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized rani-
bizumab treatment in patients with diabetic macular edema: the RESTORE extension
study. Ophthalmology. 2014;121:1045-53.
9. Eylea
®
and Lucentis
®
SPC (Summaries of Product Characteristics).
10. Hutton D, Newman-Casey PA, Tavag M, et al. Switching to less expensive blindness
drug could save medicare art B $18 billion over a ten-year period. Health Aff (Millwood)
2014;33:931-9.
11. Anothaisintawee T, Leelahavarong P, Ratanapakorn T, et al. The use of comparative
effectiveness research to linform policy decisions on the inclusion of bevacizumab for
the treatment of macular diseases in Thailand’s pharmaceutical bene%t package. Clini-
coecon Outcomes Res. 2012;4:361-74.
12. Avery RL, Castellarin AA, Steinle NC. Systemic pharmacokinetics and pharmacodyna-
mics of intravitreal a`ibercept, bevacizumab, and ranibizumab. Retina. 2017 0:1-12.
13. Meyer CH, Krohne TU, Holz FG. Intraocular pharmacokinetics after a single intravitreal
injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina. 2011;31:1877-
1884.
14. Csaky KG, Gordiyenko N, Rabena MG, Avery RL. Pharmacokinetics of intravitreal beva-
cizumab in humans. Presented at: Annual Meeting of The Association for Research in
Vision and Ophthalmology. May 6-10, 2007; Ft. Lauderdale, FL. Abstract 4936.
15. Xu L, Lu T, Tuomi L, et al. Pharmacokinetics of ranibizumab in patients with neovascular
age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci.
2013;54: 1616-1624.
16. Yu L, Liang XH, Ferrara N. Comparing protein VEGF inhibitors: In vitro biological stu-
dies. Biochem Biophys Res Commun. 2011;408 (2):276-281.
17. Massin P, Bandello F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp
D, Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Safety and ef%cacy
of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomi-
zed, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010;33
(11):2399-2405.
18. Prünte C, Fajnkuchen F, Mahmood S et al. Ranibizumab 0.5 mg treat-and-extend regi-
men for diabetic macular oedema: the RETAIN study. Br J Ophthalmol. 2016:100(6):787-
95.
19. Chen G, Li W, Tzekov R, Jiang F, Mao S, Tong Y: Ranibizumab monotherapy or combi-
ned with laser versus laser monotherapy for diabetic macular edema: a meta-analysis of
randomized controlled trials. PLoS One 2014; 9:e115797.
20. Brown DM, Schmidt-Erfurth U, Do DV. Intravitreal A`ibercept for Diabetic Macu-
lar Edema100-Week Results From the VISTA and VIVID Studies. Ophthalmology.
2015;122:2044-2052.
21. Wells JA, Glassman AR, Ayala AR, JampolLM, Bressler NM, Bressler SB, Brucker AJ,
Ferris FL, Hampton GR, Jhaveri C, Melia M, Beck RW: A`ibercept, bevacizumab, or
ranibizumab for diabetic macular edema: two year results from a comparative effective-
ness randomized clinical trial. Ophthalmology. 2016; 123: 1351-1359.
22. Yanyah A, Aytug B, Horozoglu F, Nohutcu AF. Bevacizumab for DME in previously
vitrectomized eyes. Am J Ophthalmol.
2007;144:124-126
.
23. Mehta S, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for the treatment of refrac-
tory diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010; 41 (3):323-329.
24. Lee SS, Ghosn C, Yu Z, et al. Vitreous VEGF clearance is increased after vitrectomy.
Invest Ophthalmol Vis Sci. 2009;51:2135-2138.